NASDAQ:VTGN VistaGen Therapeutics Q4 2026 Earnings Report $0.66 +0.03 (+5.14%) Closing price 04:00 PM EasternExtended Trading$0.63 -0.03 (-5.23%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast VistaGen Therapeutics EPS ResultsActual EPS-$0.37Consensus EPS -$0.34Beat/MissMissed by -$0.03One Year Ago EPS-$1.67VistaGen Therapeutics Revenue ResultsActual Revenue$0.38 millionExpected Revenue$0.40 millionBeat/MissMissed by -$16.50 thousandYoY Revenue GrowthN/AVistaGen Therapeutics Announcement DetailsQuarterQ4 2026Date6/15/2026TimeBefore Market OpensConference Call DateMonday, June 15, 2026Conference Call Time4:00PM ETUpcoming EarningsVistaGen Therapeutics' Q1 2027 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) VistaGen Therapeutics Earnings HeadlinesVistaGen Therapeutics (VTGN) to Post Earnings on WednesdayJune 24 at 1:26 AM | americanbankingnews.comVistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term GrowthJune 17, 2026 | tipranks.comElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon Musk has been quietly doubling down on it, even attempting to deploy it during his time at DOGE before being shut down. Investing legend Jeff Brown - who identified Bitcoin, Tesla, and Nvidia early - has spent six years analyzing this sector he calls 'W.T.E.' He believes it could be 90 times bigger than AI and 1,900 times bigger than Bitcoin.June 24 at 1:00 AM | Brownstone Research (Ad)Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate UpdateJune 15, 2026 | businesswire.comVistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety DisorderJune 9, 2026 | businesswire.comKuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law FirmJune 1, 2026 | prnewswire.comSee More VistaGen Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like VistaGen Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VistaGen Therapeutics and other key companies, straight to your email. Email Address About VistaGen TherapeuticsVistaGen Therapeutics (NASDAQ:VTGN) (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions. The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain. VistaGen also develops PH-10, a topical neuroactive small molecule in clinical development for psoriasis and atopic dermatitis. To broaden its development reach, VistaGen has entered strategic partnerships, including a licensing agreement with Yuhan Corporation for AV-101 in South Korea, and continues to advance its clinical and regulatory strategy primarily in North America and Asia. VistaGen’s proprietary Human Clinical Drug Rescue and ReRationalization platform employs patient-derived pluripotent stem cell–derived neural and cardiac cells to predict clinical efficacy and safety, reduce late-stage development risk and complement traditional preclinical models. This platform supports both in-house pipeline programs and collaborative research initiatives. Leading the company is President and Chief Executive Officer Shawn K. Singh, who has overseen VistaGen’s research and corporate development efforts since joining in 2014 and remains committed to translating innovative science into new therapeutic options for underserved patient populations.View VistaGen Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why KB Home Could Reward Patient Investors LaterWhy nVent Could Be a Long-Term AI Infrastructure WinnerChevron’s Microsoft Deal Turns Natural Gas Into an AI TradeMicron’s Sudden Plunge May Be an AI Buying ChanceMarathon Petroleum Is Back, But Cycles Still MatterLiquid Gold: The AI Cooling Retrofit TradeCopa Holdings May Be the Airline Stock Built to Break Out Upcoming Earnings NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)ASML (7/15/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
